Macquarie maintains outperform rating on Fortis Healthcare

Mumbai: Macquarie Research has maintained outperform rating on Fortis Healthcare along with target price of Rs 275. Fortis looks well positioned to capitalise on the significant opportunity in India's fast-growing healthcare industry and is our preferred pick in this space, the brokerage said in a note today.

"With improving efficiencies in Fortis Escorts (FEHI), Fortis Memorial Research Institute (FMRI) and SRL Diagnostics (SRL), FORH (Fortis Healthcare) looks well poised to deliver profitable growth. We believe a demerger and separate listing of SRL will help unlock significant value for shareholders," said Macquarie.

The brokerage added that current levels provide an attractive entry point to buy the stock from a one year perspective.